Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AGLNYSE:HIMSNASDAQ:NTRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGLAgilon Health$2.29-4.0%$2.69$1.50▼$7.73$941.74M0.164.78 million shs731,388 shsHIMSHims & Hers Health$47.06-1.9%$51.02$13.47▼$72.98$10.56B2.0323.21 million shs8.05 million shsNTRANatera$161.48+0.5%$159.78$92.14▼$183.00$22.15B1.731.42 million shs241,456 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGLAgilon Health+3.46%+8.39%+7.66%-41.13%-60.56%HIMSHims & Hers Health-4.14%+11.37%-15.63%+53.63%+123.48%NTRANatera-4.87%-6.49%+2.95%+12.23%+49.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGLAgilon Health2.1683 of 5 stars4.11.00.00.02.40.00.6HIMSHims & Hers Health2.1142 of 5 stars2.02.00.00.01.83.31.9NTRANatera2.12 of 5 stars2.52.00.00.03.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGLAgilon Health 2.17Hold$4.79109.44% UpsideHIMSHims & Hers Health 1.92Reduce$39.58-15.88% DownsideNTRANatera 3.00Buy$184.6314.33% UpsideCurrent Analyst Ratings BreakdownLatest AGL, NTRA, FME, and HIMS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025HIMSHims & Hers HealthTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$45.006/23/2025HIMSHims & Hers HealthCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell ➝ Sell6/23/2025HIMSHims & Hers HealthUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$30.006/23/2025HIMSHims & Hers HealthUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderperform ➝ Underperform6/23/2025HIMSHims & Hers HealthNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold6/11/2025HIMSHims & Hers HealthMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingEqual Weight ➝ Equal Weight$40.006/4/2025HIMSHims & Hers HealthNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$61.00 ➝ $65.005/15/2025NTRANateraPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$205.00 ➝ $210.005/13/2025AGLAgilon HealthWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$6.00 ➝ $5.005/9/2025NTRANateraUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$211.00 ➝ $218.005/9/2025NTRANateraBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$160.00 ➝ $190.00(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGLAgilon Health$6.06B0.16N/AN/A$1.14 per share2.00HIMSHims & Hers Health$1.48B7.13$0.33 per share141.55$2.16 per share21.78NTRANatera$1.70B12.99N/AN/A$9.05 per share17.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGLAgilon Health-$260.15M-$0.59N/AN/AN/A-4.04%-45.47%-12.76%8/5/2025 (Estimated)HIMSHims & Hers Health$126.04M$0.6968.3490.491.889.24%22.75%15.51%8/4/2025 (Estimated)NTRANatera-$190.43M-$1.47N/AN/AN/A-10.36%-18.29%-11.68%8/14/2025 (Estimated)Latest AGL, NTRA, FME, and HIMS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025NTRANatera-$0.59-$0.50+$0.09-$0.50$446.68 million$501.83 million5/6/2025Q1 2025AGLAgilon Health-$0.01$0.03+$0.04$0.03$1.50 billion$1.53 billion5/5/2025Q1 2025HIMSHims & Hers Health$0.12$0.20+$0.08$0.20$535.21 million$586.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGLAgilon HealthN/AN/AN/AN/AN/AHIMSHims & Hers HealthN/AN/AN/AN/AN/ANTRANateraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGLAgilon HealthN/A1.201.20HIMSHims & Hers HealthN/A1.591.32NTRANateraN/A3.873.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGLAgilon HealthN/AHIMSHims & Hers Health63.52%NTRANatera99.90%Insider OwnershipCompanyInsider OwnershipAGLAgilon Health3.57%HIMSHims & Hers Health17.71%NTRANatera7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGLAgilon Health1,076413.95 million399.17 millionNot OptionableHIMSHims & Hers Health1,637223.83 million184.19 millionOptionableNTRANatera4,434136.55 million126.17 millionOptionableAGL, NTRA, FME, and HIMS HeadlinesRecent News About These CompaniesRobeco Institutional Asset Management B.V. Purchases Shares of 11,600 Natera, Inc. (NASDAQ:NTRA)July 2 at 4:16 AM | marketbeat.comNatera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRDJuly 1 at 4:05 PM | businesswire.comMirae Asset Global Investments Co. Ltd. Has $8.07 Million Position in Natera, Inc. (NASDAQ:NTRA)July 1 at 4:34 AM | marketbeat.comQ1 Immuno-Oncology Earnings Review: First Prize Goes to Natera (NASDAQ:NTRA)June 30 at 6:29 AM | msn.comK.J. Harrison & Partners Inc Acquires 4,000 Shares of Natera, Inc. (NASDAQ:NTRA)June 29 at 6:23 AM | marketbeat.comSumitomo Mitsui Trust Group Inc. Boosts Holdings in Natera, Inc. (NASDAQ:NTRA)June 29 at 5:48 AM | marketbeat.comNatera, Inc. (NASDAQ:NTRA) Shares Sold by Allspring Global Investments Holdings LLCJune 29 at 5:32 AM | marketbeat.comAsset Management One Co. Ltd. Acquires New Shares in Natera, Inc. (NASDAQ:NTRA)June 29 at 3:44 AM | marketbeat.comColonial River Investments LLC Invests $441,000 in Natera, Inc. (NASDAQ:NTRA)June 28, 2025 | marketbeat.comJag Capital Management LLC Raises Stake in Natera, Inc. (NASDAQ:NTRA)June 28, 2025 | marketbeat.comArtemis Investment Management LLP Boosts Stake in Natera, Inc. (NASDAQ:NTRA)June 27, 2025 | marketbeat.comOppenheimer Asset Management Inc. Trims Stake in Natera, Inc. (NASDAQ:NTRA)June 27, 2025 | marketbeat.comHere's How Much $100 Invested In Natera 10 Years Ago Would Be Worth TodayJune 26, 2025 | benzinga.comStanley Druckenmiller's Updated Portfolio: 7 Top Stocks in 2025June 26, 2025 | money.usnews.com1 Volatile Stock to Own for Decades and 2 to Brush OffJune 26, 2025 | msn.comEnvestnet Portfolio Solutions Inc. Sells 2,578 Shares of Natera, Inc. (NASDAQ:NTRA)June 25, 2025 | marketbeat.comNatera, Inc. (NASDAQ:NTRA) Receives $184.63 Consensus Price Target from AnalystsJune 25, 2025 | americanbankingnews.comChevy Chase Trust Holdings LLC Acquires 16,678 Shares of Natera, Inc. (NASDAQ:NTRA)June 24, 2025 | marketbeat.comNarwhal Capital Management Has $1.41 Million Stake in Natera, Inc. (NASDAQ:NTRA)June 24, 2025 | marketbeat.comQ1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology StocksJune 23, 2025 | msn.com2,042 Shares in Natera, Inc. (NASDAQ:NTRA) Acquired by Whalen Wealth Management Inc.June 23, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Blockchain Stocks to Profit in a Decentralized WorldBy Chris Markoch | June 24, 2025View 3 Blockchain Stocks to Profit in a Decentralized WorldScience Applications International Is a Wicked Hot Buy in JuneBy Thomas Hughes | June 9, 2025View Science Applications International Is a Wicked Hot Buy in JuneForget the Fed: Home Depot Is the Real Gauge of the U.S. ConsumerBy Jeffrey Neal Johnson | June 19, 2025View Forget the Fed: Home Depot Is the Real Gauge of the U.S. ConsumerGeospace Stock Skyrockets After Major Petrobras ContractBy Jeffrey Neal Johnson | June 24, 2025View Geospace Stock Skyrockets After Major Petrobras ContractAeroVironment Will Hit New Highs This Year: Bull Flag ConfirmedBy Thomas Hughes | June 25, 2025View AeroVironment Will Hit New Highs This Year: Bull Flag ConfirmedAGL, NTRA, FME, and HIMS Company DescriptionsAgilon Health NYSE:AGL$2.28 -0.10 (-3.99%) As of 11:18 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.Hims & Hers Health NYSE:HIMS$47.06 -0.91 (-1.89%) As of 11:19 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.Natera NASDAQ:NTRA$161.48 +0.76 (+0.47%) As of 11:19 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock 3 Utility Stocks That Combine Income and Stability 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Why Realty Income’s 5.59% Yield Makes It a Must-Buy REIT Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
